Title |
Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab
|
---|---|
Published in |
Journal of Ophthalmic Inflammation and Infection, July 2016
|
DOI | 10.1186/s12348-016-0095-y |
Pubmed ID | |
Authors |
Arjun B. Sood, Gokul Kumar, Joshua Robinson |
Abstract |
The purpose of this study is to report a case of bilateral acute retinal necrosis in a patient with multiple sclerosis treated with natalizumab. This study is a case report and literature review. A 34-year-old Caucasian female with multiple sclerosis presented with 1 week of blurry vision in both eyes during treatment with natalizumab. Clinical examination revealed bilateral acute retinal necrosis. The patient was treated with systemic intravenous acyclovir and intravitreal injections foscarnet and ganciclovir. Natalizumab therapy was also discontinued. Natalizumab is a potent immunosuppressive agent used in relapsing remitting multiple sclerosis and Crohn's disease. The use of this medication is commonly associated with opportunistic infections in the CNS. In rare cases, ocular opportunistic infections may occur and can lead to significant visual impairment and blindness. Neurologists and ophthalmologists should be aware of this potential complication. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 4% |
Unknown | 25 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 4 | 15% |
Student > Doctoral Student | 3 | 12% |
Other | 2 | 8% |
Student > Bachelor | 2 | 8% |
Researcher | 2 | 8% |
Other | 5 | 19% |
Unknown | 8 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 38% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
Neuroscience | 2 | 8% |
Economics, Econometrics and Finance | 1 | 4% |
Nursing and Health Professions | 1 | 4% |
Other | 1 | 4% |
Unknown | 9 | 35% |